Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 ( <scp>SGLT2)</scp> inhibitors compared with glucagon‐like peptide‐1 receptor agonists ( <scp>GLP</scp> ‐1 <scp>RAs)</scp> : A pooled analysis of type 2 diabetes trials-Reference-Cited by-同舟云学术

Larger effect size in composite kidney outcomes than in major cardiovascular events associated with sodium‐glucose cotransporter‐2 ( SGLT2) inhibitors compared with glucagon‐like peptide‐1 receptor agonists ( GLP ‐1 RAs) : A pooled analysis of type 2 diabetes trials

Published:2022-09-23 Issue:1 Volume:25 Page:166-176
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obesity Metabolism

Author:

Diallo Alhassane¹^ORCID,Carlos‐Bolumbu Miguel²,Renard Pr Eric³^ORCID,Galtier Florence¹^ORCID

Affiliation:

1. INSERM, CIC 1411, Clinical Investigation Center 1411 INSERM, CHU Montpellier, Univ Montpellier Montpellier Cedex 5 France

2. Department of Anaesthesia and Intensive Care Urgences réanimation centre hospitalier Sud Essonnes CHSE Paris France

3. Department of Endocrinology and Diabetes, Montpellier University Hospital; INSERM CIC 1411 Clinical Investigation Centre Institute of Functional Genomics, University of Montpellier, CNRS, INSERM Montpellier France

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14859

Reference29 articles.

1. IDF Diabetes Atlas: Global estimates of the prevalence of diabetes for 2011 and 2030

2. Worldwide access to treatment for end-stage kidney disease: a systematic review

3. Association of Cardiometabolic Multimorbidity With Mortality

4. Department of Health and Human Services. Guidance for Industry on Diabetes Mellitus–Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes; Availability. Food and Drug Administration [Docket No. FDA–2008–D–0118].

5. Sodium‐glucose cotransporter protein‐2 (SGLT‐2) inhibitors and glucagon‐like peptide‐1 (GLP‐1) receptor agonists for type 2 diabetes: systematic review and network meta‐analysis of randomised controlled trials;Palmer SC;BMJ,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nonalcoholic Fatty Liver Disease and Chronic Kidney Disease: Epidemiology, Pathogenesis, and Clinical and Research Implications;International Journal of Molecular Sciences;2022-11-01